Aurinia Pharmaceuticals Inc. [NASDAQ: AUPH] slipped around -0.56 points on Thursday, while shares priced at $15.47 at the close of the session, down -3.49%. The company report on January 23, 2021 that FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis.
– LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death -.
– LUPKYNIS demonstrated significantly improved renal response rates compared to typical standard-of-care (SoC) in clinical trials.
Aurinia Pharmaceuticals Inc. stock is now 11.86% up from its year-to-date (YTD) trading value. AUPH Stock saw the intraday high of $16.17 and lowest of $15.40 per share. The company’s 52-week high price is 20.50, which means current price is +20.11% above from all time high which was touched on 01/25/21.
Compared to the average trading volume of 3.53M shares, AUPH reached a trading volume of 5952071 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Aurinia Pharmaceuticals Inc. [AUPH]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUPH shares is $11.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Aurinia Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 25, 2021. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $34 to $28. The new note on the price target was released on November 03, 2020, representing the official price target for Aurinia Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $20, while BTIG Research analysts kept a Buy rating on AUPH stock.
The Average True Range (ATR) for Aurinia Pharmaceuticals Inc. is set at 1.10, with the Price to Sales ratio for AUPH stock in the period of the last 12 months amounting to 16693.32. The Price to Book ratio for the last quarter was 4.90.
How has AUPH stock performed recently?
Aurinia Pharmaceuticals Inc. [AUPH] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.43. With this latest performance, AUPH shares gained by 15.79% in over the last four-week period, additionally plugging by 6.62% over the last 6 months – not to mention a drop of -21.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AUPH stock in for the last two-week period is set at 51.19, with the RSI for the last a single of trading hit 48.47, and the three-weeks RSI is set at 51.97 for Aurinia Pharmaceuticals Inc. [AUPH]. The present Moving Average for the last 50 days of trading for this stock 14.61, while it was recorded at 16.11 for the last single week of trading, and 14.99 for the last 200 days.
Aurinia Pharmaceuticals Inc. [AUPH]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Aurinia Pharmaceuticals Inc. [AUPH] shares currently have an operating margin of -23977.99. Aurinia Pharmaceuticals Inc.’s Net Margin is presently recorded at -38945.28.
Return on Total Capital for AUPH is now -39.80, given the latest momentum, and Return on Invested Capital for the company is -64.64. Return on Equity for this stock declined to -64.64, with Return on Assets sitting at -52.77.
Reflecting on the efficiency of the workforce at the company, Aurinia Pharmaceuticals Inc. [AUPH] managed to generate an average of -$2,650,499 per employee. Receivables Turnover for the company is 1.09 with a Total Asset Turnover recorded at a value of 0.00.
Earnings analysis for Aurinia Pharmaceuticals Inc. [AUPH]
With the latest financial reports released by the company, Aurinia Pharmaceuticals Inc. posted -0.22/share EPS, while the average EPS was predicted by analysts to be reported at -0.12/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -83.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AUPH.
Insider trade positions for Aurinia Pharmaceuticals Inc. [AUPH]
There are presently around $1,005 million, or 55.87% of AUPH stock, in the hands of institutional investors. The top three institutional holders of AUPH stocks are: HEALTHCOR MANAGEMENT, L.P. with ownership of 8,873,953, which is approximately -6.604% of the company’s market cap and around 9.77% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 5,172,683 shares of the stock with an approximate value of $80.02 million in AUPH stocks shares; and FMR LLC, currently with $75.53 million in AUPH stock with ownership of nearly -18.144% of the company’s market capitalization.
Positions in Aurinia Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 99 institutional holders increased their position in Aurinia Pharmaceuticals Inc. [NASDAQ:AUPH] by around 19,816,421 shares. Additionally, 44 investors decreased positions by around 13,292,420 shares, while 19 investors held positions by with 31,837,899 shares. The mentioned changes placed institutional holdings at 64,946,740 shares, according to the latest SEC report filing. AUPH stock had 32 new institutional investments in for a total of 6,127,361 shares, while 19 institutional investors sold positions of 7,372,847 shares during the same period.